Can Erdem Kara to Lead Humanis' Cardiometabolic Diseases Strategy

Humanis has assigned responsibility for promotional activities in the cardiometabolic diseases field, which holds an important place in its growth strategy, to experienced executive Can Erdem Kara. In addition to his current duties, Kara will lead growth efforts in this new therapeutic area starting in June.

Humanis, one of Turkey's healthcare sector companies, aims to strengthen its chronic disease-focused growth strategy by expanding its portfolio in the cardiometabolic diseases field. The company has made a new organizational restructuring in this direction.

Can Erdem Kara, currently serving as Promotion Manager for virology, cardiology and rare diseases at Humanis, has now also been assigned responsibility for promotional activities in the cardiometabolic diseases field.

Will Lead Growth Strategy for New Therapeutic Area
In the cardiometabolic diseases field, where Humanis will operate for the first time, Kara will lead the development of product launch and marketing strategies. In addition, structuring physician-focused scientific communication processes, adapting field teams to the new portfolio and managing training processes will be among his responsibilities.

The company views the cardiometabolic diseases field as a strategic investment area both in terms of growth potential and the goal of reaching larger patient populations.

Over 20 Years of Experience in the Sector
Can Erdem Kara began his pharmaceutical industry career in 2005 as a medical representative at Mustafa Nevzat İlaç. He later held positions at the same company as product manager for oncology and hematology, regional manager and sales manager.

Joining Humanis in 2017, Kara took on important roles in the company's marketing and field operations through promotional activities in virology, cardiology and rare diseases.

With his new role starting in June 2026, Kara will be responsible for implementing Humanis's growth strategies in the cardiometabolic diseases field.

Cardiometabolic Diseases Market Growing
Cardiometabolic diseases, which encompass interrelated health problems such as diabetes, obesity, hypertension and cardiovascular diseases, rank among the most important agenda items for healthcare systems worldwide. An aging population, lifestyle changes and the increase in chronic diseases are driving up demand for treatments and health solutions in this field.